{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:02:20Z","timestamp":1789974140861,"version":"4.0.1"},"reference-count":46,"publisher":"China Science Publishing & Media Ltd.","issue":"9","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.3724\/abbs.2025210","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:47:46Z","timestamp":1762332466000},"page":"2113-2124","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Andrographolide suppresses triple-negative breast cancer proliferation through the p53\/CDK1 axis: a multiscale analysis combining network pharmacology and machine learning"],"prefix":"10.3724","volume":"58","author":[{"given":"Xiaoyong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhensheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhai","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijian","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","volume":"50","author":"Akram M","year":"2017","unstructured":"Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res, 2017, 50:","journal-title":"Biol Res"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","volume":"27","author":"Howard FM","year":"2021","unstructured":"Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer. Cancer J, 2021, 27: 8-16.","journal-title":"Cancer J"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"Yin L","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res, 2020, 22:","journal-title":"Breast Cancer Res"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"Derakhshan F","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol Mech Dis, 2022, 17: 181-204.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Li Y","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol, 2022, 15:","journal-title":"J Hematol Oncol"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","volume":"212","author":"Karim AM","year":"2023","unstructured":"Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, Park DW. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol, 2023, 212:","journal-title":"Biochem Pharmacol"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"Garrido-Castro AC","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov, 2019, 9: 176-198.","journal-title":"Cancer Discov"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","volume":"293","author":"Kumar P","year":"2016","unstructured":"Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet, 2016, 293: 247-269.","journal-title":"Arch Gynecol Obstet"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","volume":"72","author":"Borri F","year":"2021","unstructured":"Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol, 2021, 72: 136-145.","journal-title":"Semin Cancer Biol"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"151548","DOI":"10.1016\/j.soncn.2023.151548","volume":"40","author":"Patel G","year":"2024","unstructured":"Patel G, Prince A, Harries M. Advanced triple-negative breast cancer. Semin Oncol Nurs, 2024, 40:","journal-title":"Semin Oncol Nurs"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3390\/ijerph17062078","volume":"17","author":"Medina MA","year":"2020","unstructured":"Medina MA, Oza G, Sharma A, Arriaga LG, Hern\u00e1ndez Hern\u00e1ndez JM, Rotello VM, Ramirez JT. Triple-negative breast cancer: a review of conventional and advanced therapeutic strategies. Int J Environ Res Public Health, 2020, 17:","journal-title":"Int J Environ Res Public Health"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"113954","DOI":"10.1016\/j.jep.2021.113954","volume":"272","author":"Jiang M","year":"2021","unstructured":"Jiang M, Sheng F, Zhang Z, Ma X, Gao T, Fu C, Li P.  Andrographis paniculata (Burm.f.) nees and its major constituent andrographolide as potential antiviral agents . J Ethnopharmacol, 2021, 272:","journal-title":"J Ethnopharmacol"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/ptr.7324","volume":"36","author":"Zeng B","year":"2022","unstructured":"Zeng B, Wei A, Zhou Q, Yuan M, Lei K, Liu Y, Song J. Andrographolide: a review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches. PhytoTher Res, 2022, 36: 336-364.","journal-title":"PhytoTher Res"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1875-5364(20)60016-4","volume":"18","author":"Latif R","year":"2020","unstructured":"Latif R, Wang CY. Andrographolide as a potent and promising antiviral agent. Chin J Nat Meds, 2020, 18: 760-769.","journal-title":"Chin J Nat Meds"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/molecules26010005","volume":"26","author":"Burgos RA","year":"2021","unstructured":"Burgos RA, Alarc\u00f3n P, Quiroga J, Manosalva C, Hancke J. Andrographolide, an anti-inflammatory multitarget drug: all roads lead to cellular metabolism. Molecules, 2021, 26:","journal-title":"Molecules"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"117438","DOI":"10.1016\/j.biopha.2024.117438","volume":"180","author":"Hu J","year":"2024","unstructured":"Hu J, Li Y, Xie X, Song Y, Yan W, Luo Y, Jiang Y. The therapeutic potential of andrographolide in cancer treatment. Biomed Pharmacother, 2024, 180:","journal-title":"Biomed Pharmacother"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"e0240020","DOI":"10.1371\/journal.pone.0240020","volume":"15","author":"Wanandi SI","year":"2020","unstructured":"Wanandi SI, Limanto A, Yunita E, Syahrani RA, Louisa M, Wibowo AE, Arumsari S.  In silico and in vitro studies on the anti-cancer activity of andrographolide targeting survivin in human breast cancer stem cells . PLoS One, 2020, 15:","journal-title":"PLoS One"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"596652","DOI":"10.3389\/fphar.2021.596652","volume":"12","author":"Luo W","year":"2021","unstructured":"Luo W, Jia L, Zhang JW, Wang DJ, Ren Q, Zhang W. Andrographolide against lung cancer-new pharmacological insights based on high-throughput metabolomics analysis combined with network pharmacology. Front Pharmacol, 2021, 12:","journal-title":"Front Pharmacol"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cbi.2017.06.024","volume":"273","author":"Shi L","year":"2017","unstructured":"Shi L, Zhang G, Zheng Z, Lu B, Ji L. Andrographolide reduced VEGFA expression in hepatoma cancer cells by inactivating HIF-1\u03b1: the involvement of JNK and MTA1\/HDCA. Chem-Biol Interact, 2017, 273: 228-236.","journal-title":"Chem-Biol Interact"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"6686","DOI":"10.3390\/molecules27196686","volume":"27","author":"Othman NS","year":"2022","unstructured":"Othman NS, Mohd Azman DK. Andrographolide induces G2\/M cell cycle arrest and apoptosis in human glioblastoma DBTRG-05MG cell line via ERK1\/2\/c-Myc\/p53 signaling pathway. Molecules, 2022, 27:","journal-title":"Molecules"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1080\/01635581.2020.1828942","volume":"73","author":"Khan I","year":"2021","unstructured":"Khan I, Mahfooz S, Faisal M, Alatar AA, Ansari IA. Andrographolide induces apoptosis and cell cycle arrest through inhibition of aberrant hedgehog signaling pathway in colon cancer cells. Nutr Cancer, 2021, 73: 2428-2446.","journal-title":"Nutr Cancer"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13046-018-0926-9","volume":"37","author":"Peng Y","year":"2018","unstructured":"Peng Y, Wang Y, Tang N, Sun D, Lan Y, Yu Z, Zhao X. Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res, 2018, 37:","journal-title":"J Exp Clin Cancer Res"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.bcp.2009.12.014","volume":"79","author":"Zhou J","year":"2010","unstructured":"Zhou J, Ong CN, Hur GM, Shen HM. Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem Pharmacol, 2010, 79: 1242-1250.","journal-title":"Biochem Pharmacol"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"115327","DOI":"10.1016\/j.bcp.2022.115327","volume":"206","author":"Chou YJ","year":"2022","unstructured":"Chou YJ, Lin CC, Hsu YC, Syu JL, Tseng LM, Chiu JH, Lo JF. Andrographolide suppresses the malignancy of triple-negative breast cancer by reducing THOC1-promoted cancer stem cell characteristics. Biochem Pharmacol, 2022, 206:","journal-title":"Biochem Pharmacol"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"116306","DOI":"10.1016\/j.jep.2023.116306","volume":"309","author":"Zhao L","year":"2023","unstructured":"Zhao L, Zhang H, Li N, Chen J, Xu H, Wang Y, Liang Q. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. J Ethnopharmacol, 2023, 309:","journal-title":"J Ethnopharmacol"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","volume":"43","author":"Nogales C","year":"2022","unstructured":"Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt HHHW. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci, 2022, 43: 136-150.","journal-title":"Trends Pharmacol Sci"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s12672-024-01641-6","volume":"15","author":"Luo P","year":"2024","unstructured":"Luo P, Huang C, Guo J, Yao X, Pan C, Bao A, Li F. Network pharmacology and anticancer mechanism study of Dendrobium nobile dendrobine in the treatment of colorectal cancer. Discov Oncol, 2024, 15:","journal-title":"Discov Oncol"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jpha.2023.03.006","volume":"13","author":"Qu L","year":"2023","unstructured":"Qu L, Liu Y, Deng J, Ma X, Fan D. Ginsenoside Rk3 is a novel PI3K\/AKT-targeting therapeutics agent that regulates autophagy and apoptosis in hepatocellular carcinoma. J Pharm Anal, 2023, 13: 463-482.","journal-title":"J Pharm Anal"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1017\/erm.2020.3","volume":"22","author":"Smith HL","year":"2020","unstructured":"Smith HL, Southgate H, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Rev Mol Med, 2020, 22:","journal-title":"Expert Rev Mol Med"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1368-8375(03)00146-5","volume":"40","author":"Wada S","year":"2004","unstructured":"Wada S, Yue L, Furuta I. Prognostic significance of p34cdc2 expression in tongue squamous cell carcinoma. Oral Oncol, 2004, 40: 164-169.","journal-title":"Oral Oncol"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.2174\/1871520620666200203125712","volume":"20","author":"Izadi S","year":"2020","unstructured":"Izadi S, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, Yousefi M. CDK1 in breast cancer: implications for theranostic potential. Anticancer Agents Med Chem, 2020, 20: 758-767.","journal-title":"Anticancer Agents Med Chem"},{"key":"CITATION32","doi-asserted-by":"publisher","DOI":"10.1002\/cpbi.27","volume":"58","author":"Amberger JS","year":"2017","unstructured":"Amberger JS, Hamosh A. Searching online mendelian inheritance in man (OMIM): a knowledgebase of human genes and genetic phenotypes. Curr Protoc Bioinformatics, 2017, 58:","journal-title":"Curr Protoc Bioinformatics"},{"key":"CITATION33","doi-asserted-by":"crossref","unstructured":"Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Stein TI, et al. The genecards suite: from gene data mining to disease genome sequence analyses.  Curr Protoc Bioinformatics  2016, 54: 1.30.31\u201331.30.33 .","DOI":"10.1002\/cpbi.5"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"Szklarczyk D","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res, 2023, 51: D638-D646.","journal-title":"Nucleic Acids Res"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"Shannon P","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003, 13: 2498-2504.","journal-title":"Genome Res"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"e0184129","DOI":"10.1371\/journal.pone.0184129","volume":"12","author":"Chen L","year":"2017","unstructured":"Chen L, Zhang YH, Wang SP, Zhang YH, Huang T, Cai YD, Liu B. Prediction and analysis of essential genes using the enrichments of gene ontology and KEGG pathways. PLoS One, 2017, 12:","journal-title":"PLoS One"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"W60","DOI":"10.1093\/nar\/gky311","volume":"46","author":"Franz M","year":"2018","unstructured":"Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader GD, Morris Q. GeneMANIA update 2018. Nucleic Acids Res, 2018, 46: W60-W64.","journal-title":"Nucleic Acids Res"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10142-023-01016-0","volume":"23","author":"Li Z","year":"2023","unstructured":"Li Z, Qin Y, Liu X, Chen J, Tang A, Yan S, Zhang G. Identification of predictors for neurological outcome after cardiac arrest in peripheral blood mononuclear cells through integrated bioinformatics analysis and machine learning. Funct Integr Genomics, 2023, 23:","journal-title":"Funct Integr Genomics"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Tang Z","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res, 2019, 47: W556-W560.","journal-title":"Nucleic Acids Res"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"W463","DOI":"10.1093\/nar\/gkaf361","volume":"53","author":"Schake P","year":"2025","unstructured":"Schake P, Bolz SN, Linnemann K, Schroeder M. PLIP 2025: introducing protein-protein interactions to the protein-ligand interaction profiler. Nucleic Acids Res, 2025, 53: W463-W465.","journal-title":"Nucleic Acids Res"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/biom9120789","volume":"9","author":"Abu Samaan TM","year":"2019","unstructured":"Abu Samaan TM, Samec M, Liskova A, Kubatka P, B\u00fcsselberg D. Paclitaxel\u2019s mechanistic and clinical effects on breast cancer. Biomolecules, 2019, 9:","journal-title":"Biomolecules"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"Matthews HK","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol, 2022, 23: 74-88.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/0284186X.2018.1532603","volume":"58","author":"B\u00f8ttcher TM","year":"2019","unstructured":"B\u00f8ttcher TM, Cold S, Jensen AB. Treatment of advanced HR+\/HER2\u2212 breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib. Acta Oncologica, 2019, 58: 147-153.","journal-title":"Acta Oncologica"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tcb.2021.07.001","volume":"32","author":"Liu J","year":"2022","unstructured":"Liu J, Peng Y, Wei W. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol, 2022, 32: 30-44.","journal-title":"Trends Cell Biol"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","volume":"39","author":"Freeman-Cook K","year":"2021","unstructured":"Freeman-Cook K, Hoffman RL, Miller N, Almaden J, Chionis J, Zhang Q, Eisele K. Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor. Cancer Cell, 2021, 39: 1404-1421.e11.","journal-title":"Cancer Cell"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"bbad518","DOI":"10.1093\/bib\/bbad518","volume":"25","author":"Zhang P","year":"2023","unstructured":"Zhang P, Zhang D, Zhou W, Wang L, Wang B, Zhang T, Li S. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. Brief BioInf, 2023, 25:","journal-title":"Brief BioInf"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/D42C9F043F1A401FB4811C5D5BA476B4","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025210","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/D42C9F043F1A401FB4811C5D5BA476B4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:22:07Z","timestamp":1789971727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,11,18]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2025210","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}